[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.129.152. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
October 1991

The Effects of Estrone (Ogen) on Spinal Bone Density of Postmenopausal Women

Author Affiliations

From the Departments of Medicine and Radiology (Drs Harris and Genant), University of California at San Francisco; Jerry L. Pettis Memorial Veterans Hospital Research Service, Loma Linda, Calif (Dr Baylink); Creighton University Medical Center, Omaha, Neb (Dr Gallagher); and the Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Ill (Mss Karp, McConnell, and Green and Dr Stoll).

Arch Intern Med. 1991;151(10):1980-1984. doi:10.1001/archinte.1991.00400100060010
Abstract

The effects of cyclical treatment with estrone sulfate (0.3, 0.625, or 1.25 mg), plus calcium carbonate, on spinal trabecular bone density were compared with placebo in 120 postmenopausal women in this 2-year, multicenter, doubleblind study. While the placebo and 0.3-mg treatment groups lost bone density (-3.6% and -5.1%), the 0.625- and 1.25-mg treatment groups experienced no significant change from baseline at 24 months (-0.8% and +0.7%). The 1.25-mg treatment group was significantly different from the placebo group at 12,18, and 24 months. Although the 0.625-mg treatment group was significantly different from the placebo group only at 18 months, the data suggest that 0.625 and 1.25 mg of estrone sulfate had different effects than placebo and 0.3 mg of estrone sulfate and, given with supplemental calcium, are effective doses for the prevention of spinal bone loss.

(Arch Intern Med. 1991;151:1980-1984)

×